Publications

Continued JAK Inhibitor Treatment on the Risk of Recurrent Herpes Zoster Reactivation in Patients with Immune-mediated Inflammatory Diseases: A Nationwide Population-based Study in South Korea

Semin Arthritis Rheum 2024 doi 10.1016/j.semarthrit.2024.152362 Epub ahead of print

Kim YE,

Kim YJ,

Jeong DH,

Kim S,

Kim MJ,

Kim HH,

Jo KW,

Park SH,

Hong S

This real-world study by Kim, et al. found no significant relationship between continued JAK inhibitor therapy in patients with IMIDs and the risk of subsequent recurrent HZ reactivation. They also found no significant difference in the number of days patients were treated for HZ in the JAK inhibitor continuation and discontinuation groups.

Keywords:

• JAK,
• Real-World,
• Safety

Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis

Pharmacology 2023;108(6):589–598 doi 10.1159/000527186

Lee YH,

Song GG

The results of a Bayesian network meta-analysis by Lee and Song showed that JAK inhibitors were more likely to achieve remission and LDA in DMARD-naive RA patients than MTX. However, there were no significant differences in remission rates nor LDA rates between the JAK inhibitors investigated.

Keywords:

• JAK,
• Efficacy

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

Ann Rheum Dis. 2023 doi: 10.1136/ard-2023-223916

Fleischmann R,

Curtis JR,

Charles-Schoeman C,

Mysler E,

Yamaoka K,

Richez C,

Palac H,

Dilley D,

Liu J,

Strengholt S,

Burmester G

Pots hoc analysis of safety data in patients with RA at increased risk of CV events from the upadacitinib SELECT phase III RA clinical programme helps to contextualise the overall risk profile of upadacitinib.

Keywords:

• JAK,
• Updacitinib,
• Phase 3,
• Safety,
• Cardiovascular

Toxicity Signals Associated with Secukinumab: A Pharmacovigilance Study Based on The United States Food And Drug Administration Adverse Event Reporting System Database

Br J Clin Pharmacol. 2022 doi: 10.1111/bcp.15535

Zheng Y,

Guo X,

Chen C,

Chi L,

Guo Z,

Liang J,

Wei L,

Chen X,

Ye X,

He J

This study explored the clinical characteristics, outcomes, and time to onset of the four main toxicities of secukinumab with hypersensitivity identified as the most common toxicity.

Keywords:

• IL-17,
• Secukinumab,
• Safety,
• Review

After JAK Inhibitor Failure: To Cycle Or To Switch, That Is The Question – Data From The JAK-Pot Collaboration of Registries

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222835

Pombo-Suarez M,

Sanchez-Piedra C,

Gómez-Reino J,

Lauper K,

Mongin D,

Iannone F,

Pavelka K,

Nordström DC,

Inanc N,

Codreanu C,

Hyrich KL,

Choquette D,

Strangfeld A,

Leeb BF,

Rotar Z,

Rodrigues A,

Kristianslund EK,

Kvien TK,

Elkayam O,

Lukina G,

Bergstra SA,

Finckh A,

Courvoisier DS.

Data from the JAK-pot collaboration of registries show that cycling JAKinibs and switching to a bDMARD appear to have similar effectiveness, after failing the first JAKinib.

Keywords:

• JAK,
• Meta Analysis,
• Switching

Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: A Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Trial

Ann Rheum Dis. 2022 2022 2022-222849

Brunner HI,

Foeldvari I,

Alexeeva E,

Ayaz NA,

Calvo Penades I,

Kasapcopur O,

Chasnyk VG,

Hufnagel M,

Żuber Z,

Schulert G,

Ozen S,

Rakhimyanova A,

Ramanan A,

Scott C,

Sozeri B,

Zholobova E,

Martin R,

Zhu X,

Whelan S,

Pricop L,

Martini A,

Lovell D,

Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

In the latest study by Brunner, et al. secukinumab demonstrated efficacy and safety in the JIA categories of ERA and JPsA. This phase 3 study aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA.

Keywords:

• IL-17,
• Secukinumab,
• Phase 3,
• Efficacy

Oral surveillance and JAK inhibitor safety: the theory of relativity

Nat Rev Rheumatol. 2022. Epub ahead of print doi: 10.1038/s41584-022-00767-7

Winthrop KL,

Cohen SB.

Putting the data into context, Winthrop, et al. conclude that the ORAL Surveillance data are not dissimilar to those from the original developmental programme, which suggested additional safety concerns at the 10 mg dosage and that resulted in the 5 mg twice daily dosage as the approved dose for RA.Following the recent results of the ORAL Surveillance (ORALSURV) study, and the consequent changes to the utilisation of JAKinibs, made by the regulatory authorities, Winthrop, et al. aim to put the O...

Keywords:

• JAK,
• Tofacitinib,
• Safety

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

Rheumatol Ther. 2021;8(2):903–919

Mease PJ,

Lertratanakul A,

Papp KA,

van den Bosch FE,

Tsuji S,

Dokoupilova E,

Keiserman MW,

Bu X,

Chen L,

McCaskill RM,

Zueger P,

McDearmon-Blondell EL,

Pangan AL,

Tillett W.

Fifty-six-week data suggest that upadacitinib could be a favourable long-term treatment option in patients with PsA who are refractory to biologic therapy.As the need for additional therapeutic agents that can effectively control disease activity continues, new data from a 56-week analysis of the oral reversible JAK1 inhibitor, upadacitinib, currently under investigation for the treatment of PsA, shows that efficacy of the drug is maintained over the duration of this study.Mease, et al. explored...

Keywords:

• JAK,
• Updacitinib,
• Phase 3,
• Safety,
• Efficacy

JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis

Clin Exp Rheumatol. 2021;39(3):668-675.

Crispino N,

Ciccia F.

The JAK/STAT pathway is receiving increasing attention in modulation of nociceptive responses, given its clear role in cytokine signalling. The authors of this review speculate that JAKinibs may have an effect on the modulation of nociception and reduction of pain.Crispino N, et al. review the impact of pain in patients with rheumatic disease and the physiological basis of modulating nociceptive pain. They examine the role of cytokines in the modulation of pain and analyse current clinical JAKin...

Keywords:

• JAK,
• Basic Science,
• MOA

Effects of One-Year Tofacitinib Therapy on Bone Metabolism in Rheumatoid Arthritis

Osteoporos Int 2021 Feb 9 DOI 10.1007/s00198-021-05871-0

Hamar A,

Szekanecz Z,

Pusztai A,

Czókolyová M,

Végh E,

Pethő Z,

Bodnár N,

Gulyás K,

Horváth Á,

Soós B,

Bodoki L,

Bhattoa H. P,

Nagy G,

Tajti G,

Panyi G,

Szekanecz É,

Domján A,

Hodosi K,

Szántó S,

Szűcs G,

Szamosi S

Thought to be the first study of its kind, Hamar, et al. have demonstrated the effect of one-year tofacitinib treatment on bone mineral density (BMD) in RA patients. While the association between RA and osteoporosis is well known, and evidence indicates that up to 70% of these patients have reduced BMD, little information is available on how the JAK inhibitor tofacitinib affects bone status, areal and volumetric BMD, and bone turnover markers. In this prospective study, 30 patients were assessed...

Keywords:

• JAK,
• Tofacitinib,
• Bone